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To the Editor:
The authors of the article ‘‘Potent Anticoagulants Are
Associated with a Higher All-cause Mortality Rate After
Hip and Knee Arthroplasty’’ published in March 2008 [9]
conducted a review of the literature on various thrombo-
prophylactic regimens used for prevention of venous
thromboembolism after THA or TKA. Based on an anal-
ysis of that review, they concluded so-called ‘‘potent’’
anticoagulants, Group A (low-molecular-weight heparins,
ximelagatran, fondaparinux, and rivaroxaban), were asso-
ciated with higher all-cause mortality than other
thromboprophylactic regimens, which were divided into
multimodal regimens (Group B) and warfarin (Group C).
However, there appear to be serious ﬂaws in the manner in
which the data were selected and presented and the
methods used for comparison. Therefore, we believe their
conclusions are unfounded and require further discussion.
First, the conclusions suggest all ‘‘potent’’ anticoagu-
lants are equivalent, and yet comparative Phase III trials of
fondaparinux and rivaroxaban versus enoxaparin show
clearly this is not the case [1–3, 6–8, 10]. Furthermore, no
rationale is offered for the inclusion in Group A of one
drug ximelagatran (Exanta1, AstraZeneca) that was
withdrawn because of hepatotoxicity and another drug
rivaroxaban (Xarelto1, Bayer HealthCare AG, Wuppertal,
Germany) that has not yet received regulatory approval.
Second, there is considerable variability and inconsis-
tency in the quality of data selected for analysis, shown in
Table 1. (1) Study populations selected for analysis com-
prised the safety populations for some studies but the
‘‘intention to treat’’ populations for others. (2) All except
one (shown incorrectly) of the Group B studies were
nonrandomized. (3) Despite its inclusion in Group A, no
data for rivaroxaban are mentioned anywhere in the paper.
(4) For the Group A study by Heit et al. [5], the deaths
shown include two that occurred while patients were
receiving a placebo. (5) Most Group A data presented
appear to be for enoxaparin, which therefore cannot be
considered representative of all the Group A anticoagu-
lants. (6) Most of the selected studies were not double-
blind and did not apply central, blinded adjudication of all
outcomes, implying much of the data for pulmonary emboli
were based on local reports only. Therefore, any conclu-
sions regarding pulmonary embolism must be considered
questionable. (7) With the exception of randomization,
Sharrock et al. do not discuss the extent to which the above
points might affect the validity of their analysis.
Third, questions must be asked about the methods used
for the comparisons between the groups. (1) Mortality and
pulmonary embolism rates were not corrected for different
(Re: Sharrock NE, Della Valle AG, Go G, Lyman S, Salvati EA.
Potent anticoagulants are associated with a higher all-cause mortality
rate after hip and knee arthroplasty.Clin Orthop Relat Res.
2008;466:714–721.)
B. I. Eriksson (&)
Department of Orthopaedics, Sahlgrenska University Hospital/
O ¨stra, Gothenburg 41685, Sweden
e-mail: b.eriksson@orthop.gu.se
R. J. Friedman
Department of Orthopaedic Surgery, Medical University of
South Carolina, Charleston, SC, USA
F. D. Cushner
Insall Scott Kelly Center for Orthopaedics and Sports Medicine,
New York, NY, USA
M. R. Lassen
Department of Orthopaedics, Nordsjællands Hospital,
Hoersholm, Denmark
123
Clin Orthop Relat Res (2008) 466:2009–2011
DOI 10.1007/s11999-008-0324-2durations of prophylaxis or observation. Because a sub-
stantial proportion of venous thromboembolisms occur
after hospital discharge, the absence of any such correction
considerably complicates interpretation of the analyses
presented in this article. (2) Half (30 of 60) of the Group A
deaths occurred in just three of the 12 Group A studies (see
Table 1 in Sharrock et al. [9]). Two of these studies
completed enrollment by 1996 (see Table 1 in Sharrock
et al. [9]) and are unlikely to be representative of modern
practice. Similarly, nine of the 14 Group B deaths occurred
in just one study (see Table 1 in Sharrock et al. [9]), as did
half the warfarin (Group C) deaths. These observations
make it unlikely the total number of deaths recorded for
each group can be considered representative of the corre-
sponding thromboprophylactic regimen. (3) There is
considerable heterogeneity in each group, with mortality
rates ranging from 0.00% to 0.62% for Group A, 0.00% to
0.29% for Group B, and 0.10% to 0.67% for Group C. All
three of these ranges have considerable overlap. (4) No
correction is applied for the use of general versus regional
anesthesia, even though the authors point out regional
anesthesia was used for 36% of the Group A patients versus
94% of the Group B patients.
Although Sharrock et al. conducted their analysis on the
basis of the number of deaths reported for the various
studies included, the above points indicate much of the
mortality data should either have been corrected for various
factors before inclusion in the analysis or should not have
been included at all. Without justiﬁcation for the validity of
the included data, it is difﬁcult to conclude an analysis
based on those data is valid.
Sharrock et al. [9] include only three studies (see Table 1
in Sharrock etal. [9])where Group A and Group C regimens
are compared within-study. None of the listed studies
include a within-study comparison of a Group B regimen
with either a Group A or a Group C regimen. Unfortunately,
they did not provide full details of the statistical methods
used; however, given the relative lack of within-study
comparisons, it seems unlikely their methods can provide a
valid analysis of treatment comparisons for such heteroge-
neous study data. Although the authors recognized this
limitation, the potential impact of uncontrollable bias in the




The authors note use of regional anesthesia in ortho-
paedic surgery is associated with a 30% reduction in
mortality compared with general anesthesia, although they
also argue the differences in the use of regional anesthesia
are not sufﬁcient to invalidate their claim for an excess
mortality associated with ‘‘potent’’ anticoagulants. How-
ever, in light of the above concerns about the quality of the
data and the statistical methods used, it seems possible the
imbalance in anesthetic protocols between Groups A and
B, or other factors such as case volume, could account
entirely for the authors’ observations.
More importantly, Sharrock et al. [9] do not address the
compelling arguments for anticoagulant-based thrombo-
prophylaxis set forth by Geerts et al. [4] in the current
American College of Chest Physicians guidelines. These
guideline recommendations are evidence-based, and the use
of anticoagulant thromboprophylaxis is supported by Grade
1A evidence for THA and TKA. If the authors wished to
suggest the most widely used anticoagulant-based throm-
boprophylaxis protocols are inappropriate, then their
arguments would have been considerably strengthened by
the inclusion of levels of evidence for their assertions.
We believe this paper suffers from profound defects in
data selection and methodology, and as a result, the con-
clusion that thromboprophylaxis with so-called ‘‘potent’’
anticoagulants is associated with higher all-cause mortality
is invalid.
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